ClinicalTrials.gg
RecruitingNCT05802264ABCIUpdated Feb 12, 2025

Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis

A Phase 1 interventional study of ABCI and Placebo in Cystic Fibrosis, sponsored by Cystetic Medicines, Inc.. Recruiting at 5 sites in 2 countries. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Cystetic Medicines, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Cystic Fibrosis with a site in Australia — 2 open to participants now, 5 under way, 4 of them phase 3. Cystic Fibrosis · Australia.

Planned enrollment
54th of 99
108 · median 120
Started
2023
with 3 others
Phase 1
12 of 106
1 open now
Registered
98th of 106
by date

Among the 106 studies in Cystic Fibrosis with a site in Australia, this one is the 54th largest by planned enrollment of the 99 interventional ones that give a count, is one of 4 that started in 2023, is one of 12 in phase 1, and was the 98th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 106 studies in Cystic Fibrosis with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Cystic Fibrosis with a site in Australia, or all of them as a file.
02

Study summary

This is a 3-part, single-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part A) and multiple-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part B), and a Phase 1b open-label study in subjects with CF (Part C) to assess the safety, tolerability, PK, and preliminary efficacy of ABCI. Subjects will be evaluated for eligibility during Screening within 30 days prior to Day 1 (Randomization; Visit 3). In Parts A and B, eligible healthy volunteers may be enrolled in the study and randomly allocated to treatment with ABCI or placebo as described below. In Part C, eligible subjects with CF may be enrolled in the study and receive treatment with ABCI as described below. Approximately 72 healthy subjects total will be randomized to 9 cohorts (48 subjects in 6 cohorts in Part A, 24 subjects in 3 cohorts in Part B) and approximately 36 subjects with CF will receive the low dose, medium dose (2 sentinel subjects), or high dose of ABCI in Part C.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A and Part B: Each subject must meet the following criteria to be enrolled in Part A and Part B of this study.

  • Subject has signed, dated, and received a copy of the IRB/IEC-approved written ICF.
  • Subject is male or female aged ≥18 to ≤55 years.
  • Subject has a between 18 and 32 kg/m2
  • Subject has an of >90% of predicted normal value
  • Subject has normal or clinically acceptable physical examination, vital signs, clinical laboratory values, and at Screening.
  • Female subjects must be of non- or male/female subjects of childbearing potential agree to use highly effective /preventive exposure measures

Part C: Each subject must meet the following criteria to be enrolled in Part C of this study.

  • Subject has signed, dated, and received a copy of the IRB/IEC-approved written ICF.
  • Age 16 years or older
  • Confirmed diagnosis of CF, including sweat chloride >60 mM.
  • Subject is either: Being treated with an approved CFTR modulator for at least 28 days prior to Screening, or Not being treated with a CFTR modulator
  • FEV1:
  • For subjects on CFTR modulators: FEV1 ≥40% and ≤90%
  • For subjects not on CFTR modulators: FEV1 ≥40% and ≤100%
  • Stable CF disease and treatment regiment
  • Female subjects must be of non-childbearing potential or male/female subjects of childbearing potential agree to use highly effective contraception/preventive exposure measures

Exclusion criteria

Exclusion Criteria:

Part A and Part B: Any subject who meets any of these criteria must be excluded from Part A and Part B of this study:

  • Subject has history or evidence of any pulmonary condition
  • Subject has history or evidence of any clinically significant diseases or conditions
  • Subject has history of of any type
  • Subject has an active COVID-19 infection within 4 weeks
  • Subject is positive for antibodies, surface antigen, or antibodies, or has a positive QuantiFERON®-tuberculosis Gold (QFT-G) test for tuberculosis at Screening
  • Subject has a self-reported lower respiratory tract infection within 6 weeks
  • Subject has evidence of any active or suspected bacterial, viral, fungal or parasitic infections within the past 4 weeks
  • A subject who is an active smoker or a former smoker
  • Subject has history of alcohol or drug abuse in the past year
  • Subject has tested positive for drugs (including cannabis), nicotine/cotinine, and/or alcohol use at Screening, subject has consumed alcohol within 24 hours prior to Visit 3
  • Subject has participated in any clinical study or had been treated with any drugs within 28 days or 5 half-lives
  • Female subject who is pregnant or breastfeeding.
  • Subject has any episode of paradoxical bronchospasm in the past 12 months.
  • Subject has pacemaker; is not in sinus rhythm; has a interval (QTc; using Fridericia's [QTcF] formula) of >450 ms (for males) and >470 ms (for females); or has a left bundle branch block or bifascicular block.
  • Subject has a pulse \<40 or >100 bpm; systolic blood pressure >140 mmHg, or diastolic blood pressure >90 mmHg at Screening
  • Subject has Type I or II diabetes requiring medication.
  • Subject has received any vaccine within 30 days prior to Day 1.
  • Subject has received any of the following therapies within 6 months prior to Screening: imatinib, ambrisentan, azathioprine, cyclophosphamide, cyclosporine A, bosentan, or methotrexate.
  • Subject has received any antibody or therapeutic biologic product during the 6 months prior to Screening.
  • Subject has received any oral, intravenous, or intramuscular within 4 weeks prior to Screening. Intrathecal or intraarticular steroids are permitted.
  • A subject who is not vaccinated with the COVID-19 vaccine with appropriate window from last dose of vaccine to Screening per local guidelines, policies, and availability within 30 days prior to Day 1.

Part C: Any subject who meets any of these criteria must be excluded from Part C of this study:

  • History of any illness or any clinical condition that might confound the results of the study or pose an additional risk in administering study drug(s) to the subject.
  • Any of the following abnormal laboratory tests: , Total , liver enzymes or creatine clearance
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for sinopulmonary disease within 28 days before the screening visit.
  • An acute illness not related to CF within 14 days before the first dose of study drug.
  • Subject has an active COVID-19 infection within 4 weeks prior to screening.
  • Ongoing or prior participation in a study of an investigational treatment within 28 days or 5 terminal half-lives (whichever is longer) before screening.
  • Female subject who is pregnant or breastfeeding.

Please refer to study protocol for the complete inclusion/exclusion criteria list.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Part A Healthy Volunteer

    Subjects will be assigned to one of six planned dose cohorts and receive single doses of ABCI (0.5mg, 1.0mg, 2.0mg, 4.0mg, 6.0mg, 10.0mg). In each cohort, six subjects will receive ABCI and 2 will receive placebo

    Combination Product: ABCI · Combination Product: Placebo

  • Experimental
    Part B Healthy Volunteer

    Subjects will be assigned to one of three planned dose cohorts and receive a loading dose and multiple ascending doses of ABCI (loading dose 1.5mg/0.5mg daily, loading dose 6.0mg/2.0 daily, loading dose 10.0mg/4.0mg daily). In each cohort, six subjects will receive ABCI and 2 will receive placebo.

    Combination Product: ABCI · Combination Product: Placebo

  • Experimental
    Part C People with Cystic Fibrosis

    Subjects will be assigned to one of two planned dose cohorts of ABCI (loading dose 1.5 mg/0.5 mg daily, loading dose 6.0mg/2.0mg daily, loading dose 10.0mg/4.0mg daily) for a total of 28 days of open-label study drug administration. Up to 36subjects with CF, including 2 sentinels subjects not on cystic fibrosis transmembrane conductance regulator (CFTR) modulators will be enrolled. The 2 sentinel subjects will receive the medium dose/regimen. If the medium dose/regimen is tolerated, the remaining subjects with CF may receive the low, medium, high dose/regimen of ABCI and may be either on CFTR modulators or not on CFTR modulators. It is anticipated that approximately 24 subjects will be enrolled as follows: 8 high, 8 medium, and 8 low dose/regimen.

    Combination Product: ABCI

Interventions

  • Combination productABCI

    Subjects will receive ABCI via oral inhalation

    Also known as: Amphotericin B Cystetic for Inhalation

  • Combination productPlacebo

    Subjects will receive ABCI via oral inhalation

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs), and Serious Adverse Events (SAEs)

    The safety and tolerability of ABCI following oral inhalation of single and multiple ascending doses in healthy subjects (Parts A and B), and in people with Cystic Fibrosis (Part C) will be assessed

    Time frame: up to 10 weeks

Secondary outcomes

  1. Pharmacokinetics (PK) Profile - SAD Cmax

    Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: Observed maximum concentration (Cmax)

    Time frame: 1 day

  2. Pharmacokinetics (PK) Profile - SAD Tmax

    Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: time to reach maximum concentration (Tmax)

    Time frame: 1 day

  3. Pharmacokinetics (PK) Profile - SAD AUC0-24

    Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: Area under the concentration-time curve from time 0 to 24 hours post-dose (AUC0-24)

    Time frame: 1 day

  4. Pharmacokinetics (PK) Profile - SAD AUClast

    Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)

    Time frame: 1 day

  5. Pharmacokinetics (PK) Profile - SAD AUCinf

    Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: Area under the concentration-time curve from the time of dosing extrapolated to infinity (AUCinf)

    Time frame: 1 day

  6. Pharmacokinetics (PK) Profile - SAD AUCtau

    Pharmacokinetics Characteristics in Single Ascending Dose HV Subjects: Area under the concentration- concentration-time curve over the dosing interval (AUCtau)

    Time frame: Up to 28 days

  7. Pharmacokinetics (PK) Profile - MAD Cmax

    Pharmacokinetics Characteristics in Multiple Ascending Dose HV Subjects: Observed maximum concentration (Cmax)

    Time frame: Up to 28 days

  8. Pharmacokinetics (PK) Profile - MAD Tmax

    Pharmacokinetics Characteristics in Multiple Ascending Dose HV Subjects: time to reach maximum concentration (Tmax)

    Time frame: Up to 28 days

  9. Pharmacokinetics (PK) Profile - MAD AUC0-24

    Pharmacokinetics Characteristics in Multiple Ascending Dose HV Subjects: Area under the concentration-time curve from time 0 to 24 hours post-dose (AUC0-24)

    Time frame: Up to 28 days

  10. Pharmacokinetics (PK) Profile - MAD Plasma AmB assessments

    Pharmacokinetics Characteristics in Multiple Ascending Dose HV Subjects: Plasma AmB assessments

    Time frame: Up to 84 days

  11. Pharmacokinetics (PK) Profile - MAD AmB concentrations in BAL fluid

    Pharmacokinetics Characteristics in Multiple Ascending Dose HV Subjects: AmB concentrations in BAL fluid after study drug administration

    Time frame: Up to 29 days

  12. AmB concentrations - Subjects with CF

    Cumulative effect on pre-dose AmB concentrations through Day 29 and assessment of washout through Day 42

    Time frame: Through 42 days

Other outcomes

  1. ppFEV1 - Subjects with CF

    Absolute change in percent-predicted morning pre-dose forced expiratory volume in 1 second (ppFEV1) from baseline to Day 29 and from Day 29 to Day 42

    Time frame: Up to 42 days

  2. LCI - Subjects with CF

    Absolute change in Lung Clearance Index (LCI) (where available)

    Time frame: Up to 42 days

  3. Questionnaire - Subjects with CF

    Absolute change in Cystic Fibrosis Questionnaire Revised (CFQ-R) in Subjects with Cystic Fibrosis: Revised (CFQ-R) respiratory domain score from baseline to Day 29 and to Day 42 where scores range from 0 to 100, with higher scores indicating better health.

    Time frame: Up to 42 days

  4. ppFVC - Subjects with CF

    Absolute change in percent-predicted morning pre-dose forced vital capacity (ppFVC) from baseline to Day 29 and from Day 29 to Day 42

    Time frame: Up to 42 days

  5. FVC - Subjects with CF

    Absolute change in morning pre-dose FVC from baseline to Day 29 and from Day 29 to Day 42 (mLs)

    Time frame: Up to 42 days

  6. FEV1 - Subjects with CF

    Absolute change in morning pre-dose FEV1 from baseline to Day 29 and from Day 29 to Day 42 (mLs)

    Time frame: Up to 42 days

  7. DLCO - Subjects with CF

    Absolute change in diffusing capacity of the lungs for carbon monoxide (DLCO \[expressed as percent-predicted corrected for hemoglobin\]) from baseline to Day 29

    Time frame: Up to 29 days

  8. Body weight - Subjects with CF

    Absolute change in body weight from baseline to Day 29 and from Day 29 to Day 42

    Time frame: Up to 42 days

  9. % solids in sputum - Subjects with CF

    Absolute change in % solids in sputum from baseline (optional)

    Time frame: Day 29

  10. FRI biomarkers - Subjects with CF

    Change from baseline in Functional Respiratory Imaging (FRI) biomarkers, including but not limited to airway wall volume, mucus plug volume, and blood vessel volume (where available)

    Time frame: Up to 28 days

  11. IVIVC - chloride secretion - Subjects with CF

    Change in chloride secretion in response to AmB in vitro in primary cultured nasal epithelial cells

    Time frame: Up to 42 days

  12. IVIVC - FEV1 - Subjects with CF

    Comparison of change from baseline FEV1 (ppFEV1 and absolute FEV1) (Day 29) and change in chloride secretion in response to AmB in vitro in primary cultured nasal epithelial cells

    Time frame: Up to 42 days

  13. IVIVC - ASL pH - Subjects with CF

    Change in ASL pH in response to AmB in vitro in primary cultured nasal epithelial cells

    Time frame: Up to 42 days

  14. IVIVC - FEV1 & ASL pH - Subjects with CF

    Comparison of change from baseline FEV1 (ppFEV1 and absolute FEV1) (Day 29) and ASL pH in response to AmB in vitro in primary cultured nasal epithelial cells

    Time frame: Up to 29 days

07

Study locations

5 of 5 sites recruiting
  • Canberra Hospital
    Canberra, Australian Capital Territory 2605, Australia
    Recruiting
    • Yashneel Prasad, MD · Contact
    • Joelle Bourke · Contact
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Jimmy Chien, MD · Contact
    • Tracey Burns · Contact
  • The Prince Charles Hospital
    Brisbane, Queensland 4032, Australia
    Recruiting
    • Ieuan Evans, MD · Contact
    • Michelle Wood · Contact
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
    Recruiting
    • Christopher Daley, MD · Contact
    • Corinne Van Asha · Contact
  • New Zealand Clinical Research
    Christchurch, New Zealand
    Recruiting
    • Cory Sellwood, MD · Contact
    • David Lee · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2025, 33 months after the start.

Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 33 months is above that.

Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Apr 6, 2023
StartActual
Mar 21, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05802264
Lead sponsor
Cystetic Medicines, Inc.
Collaborators
DevPro Biopharma
Responsible party
Sponsor
First posted
Apr 6, 2023
Start date
Mar 21, 2023
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Feb 12, 2025

Study contacts

Martin Burke, MD, PhD
Contact
mburke@cysteticmedicines.com
217-244-8726
Daniele Tompkins, MA
Contact
dtompkins@devprobiopharma.com
973-983-3700 ext. 205
Martin Burke, MD, PhD
study chair · Founder of cystetic Medicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion